Radiopharm Theranostics Limited
RDPTF
$0.0113
$0.01051,312.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 587.41% | 0.46% | -49.82% | -100.00% |
| Total Other Revenue | -122.34% | -97.62% | -73.06% | -24.43% | 49.18% |
| Total Revenue | -94.37% | -81.37% | -69.61% | -25.84% | 38.94% |
| Cost of Revenue | -17.38% | -5.98% | 7.54% | 40.78% | 90.85% |
| Gross Profit | -5.49% | -21.37% | -43.40% | -71.55% | -114.67% |
| SG&A Expenses | -11.43% | -5.31% | -0.02% | 6.36% | 14.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.08% | -5.71% | 4.22% | 24.56% | 51.61% |
| Operating Income | 2.12% | -8.39% | -20.22% | -34.67% | -53.90% |
| Income Before Tax | 9.41% | -9.99% | -34.66% | -51.30% | -75.14% |
| Income Tax Expenses | 495.65% | 300.46% | 148.24% | -3.77% | -69.08% |
| Earnings from Continuing Operations | 9.11% | -10.23% | -34.79% | -51.19% | -74.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -14.56% | 85.94% | -- | -- | -- |
| Net Income | 8.99% | -9.22% | -31.75% | -47.75% | -70.67% |
| EBIT | 2.12% | -8.39% | -20.22% | -34.67% | -53.90% |
| EBITDA | 1.81% | -9.97% | -23.85% | -40.78% | -63.86% |
| EPS Basic | 53.93% | 24.82% | -10.28% | -21.91% | -36.11% |
| Normalized Basic EPS | 65.16% | 42.47% | 18.99% | 9.80% | 0.24% |
| EPS Diluted | 53.93% | 24.82% | -10.28% | -21.91% | -36.11% |
| Normalized Diluted EPS | 65.16% | 42.47% | 18.99% | 9.80% | 0.24% |
| Average Basic Shares Outstanding | 241.52% | 137.13% | 23.92% | 24.45% | 25.05% |
| Average Diluted Shares Outstanding | 241.52% | 137.13% | 23.92% | 24.45% | 25.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
